Amgen announced a strategic collaboration with Swiss firm Molecular Partners to license and develop a new molecule in combination with its BiTE platform, in a deal worth up to $547 million. The molecule, called MP0310, aims to bind proteins on stromal cells to T cells, which would activate the immune system in tumors, the companies…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
